D-0149-2017 Class III Terminated
FDA drug recall D-0149-2017 was initiated by Zydus Pharmaceuticals USA Inc on Aug 3, 2016 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point. The recall status is terminated (terminated Jul 12, 2018). Affected quantity: 2,472 units.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 30, 2016
- Initiation Date
- Aug 3, 2016
- Termination Date
- Jul 12, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,472 units
Product description
BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05
Reason for recall
Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.
Distribution pattern
Nationwide
Code information
Lot #: MR3365, Exp. Feb 17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0149-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026